When Further Tests are Needed: Guidance on Prostate Imaging and Biopsy

An elevated Prostate-Specific Antigen (PSA) level is a starting point, not a diagnosis. Because PSA can rise due to benign conditions like an enlarged prostate (BPH) or inflammation (prostatitis), clinical guidelines emphasise a multi-step approach to determine if imaging or a biopsy is necessary.

1. Confirming the Trend

The first step following an abnormal PSA result (generally >4.0 ng/mL, though age-adjusted) is often repeat testing.

• Confirmation: NCI and AUA guidelines recommend repeating the PSA test in 6 to 8 weeks to account for transient elevations caused by recent exercise, ejaculation, or minor infection.
• PSA Change: Recent research suggests that if a repeat test shows a decline of >20%, the risk of clinically significant cancer is lower, and a biopsy may potentially be avoided.
• PSA Velocity: While a rapidly rising PSA is a red flag, the AUA cautions that “PSA velocity” (the rate of change over time) should not be the sole reason for a biopsy; it must be considered alongside other risk factors.

2. Risk Assessment and “PSA Density”

To improve diagnostic accuracy, clinicians look beyond the total PSA number:

• PSA Density: This is the PSA level divided by the volume of the prostate (measured via ultrasound or MRI). A higher PSA density is a stronger predictor of cancer than the PSA level alone, especially in men with large prostates.
• Clinical Findings: A suspicious finding during a Digital Rectal Exam (DRE), such as a firm lump or irregularity, significantly increases the urgency for further investigation regardless of the PSA level.
• Risk Calculators: Tools that incorporate age, race, and family history help determine the probability of “clinically significant” prostate cancer (Grade Group 2 or higher).

3. The Role of Imaging (mpMRI)

Before proceeding to a biopsy, advanced imaging is now frequently used as a “gatekeeper” or triage tool.

• mpMRI (Multiparametric MRI): The European Association of Urology (EAU) and NCI support using mpMRI to identify suspicious areas within the prostate.
• Avoiding Biopsy: If an MRI is clear (PI-RADS 3 or less) and other risk factors are low, a doctor and patient may choose to forgo a biopsy and continue observation.
• Targeted Biopsy: If the MRI identifies a suspicious lesion (PI-RADS 4 or 5), it allows for a “targeted biopsy,” where needles are precisely guided to the area of concern, increasing the likelihood of detecting aggressive cancer.

4. When is a Biopsy Appropriate?

A prostate biopsy is the only definitive way to diagnose cancer. It is generally recommended when:

• The PSA remains elevated after a confirmatory test.
• The PSA density is high.
• The mpMRI shows suspicious lesions.
• A DRE reveals an abnormal lump.
• Shared Decision-Making: For men aged 55–69, the decision must weigh the benefit of early detection against the risks of the procedure (infection, bleeding) and the potential for “overdiagnosis” of slow-growing tumours that may never cause harm.

Summary Checklist for Further Testing

Mr Collins Approach

Mr Gerry Collins views a PSA result not as a definitive verdict; he incorporates your prostate volume, your age, and the Free to Total PSA ratio to build a risk-stratified map. By using advanced tools like the Stockholm3 biomarker test and MRI-guided interpretations, he filters out the benign causes of PSA elevation, such as inflammation or BPH, ensuring that only those who truly need an intervention proceed to biopsy. 

Book an Appointment

Based in Manchester and Cheshire, Mr Gerald Collins is currently accepting private consultations for the assessment of kidney masses, haematuria, and general urological concerns. With 29 years of experience, he provides the clarity and expertise needed to move from uncertainty to a confident treatment plan.